A recent study published in the Stroke; a Journal of Cerebral Circulation found that short-duration dual antiplatelet therapy ...

This particular finding is a major advance in the field of antiplatelet therapy and in the treatment of ACS in general. The benefits of ticagrelor over clopidogrel were extremely consistent across ...

The following is a summary of “Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet ...

These documents have become too technical, too inconsistent, and rely too much on expert opinion, Marco Valgimigli argues.

Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top ...

Antiplatelet use can lead to improved cardiovascular ... risks while benefiting from the protective effects of antiplatelet ...

This unique dual formulation provides the potential benefit for smooth transition from short-term intravenous to long-term oral antiplatelet therapy. It has a plasma half-life of approximately 12 ...

The findings showed that P2Y12 inhibitors were more effective than aspirin in reducing the risk of heart attacks and strokes.

In addition, maximal medical therapy was loosely defined in CAVATAS and could consist of antiplatelet agents or anticoagulation with warfarin. Inconsistencies in medical treatment have also ...

The Cube CYP2C19 test can be used to aid clinicians in determining therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. Genomadix CubeTM CYP2C19 System identifies the CYP2C19 ...

Strategies for treating IC are aimed at improving symptoms and reducing the progression of atherosclerosis and include risk-factor modification, exercise, and antiplatelet therapy. Cilostazol and ...